Navigation Links
Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
Date:11/2/2013

1% (PegIFN/RBV) of patients. Further, AEs leading to the discontinuation of faldaprevir occurred in 1% (120mg) and 3% (240mg) of patients.

In STARTVerso™3, AEs of at least moderate intensity in the 12- and 24-week faldaprevir arms included gastrointestinal side effects, which occurred in 20% (12-week), 17% (24-week) and 6% (PegIFN/RBV alone) of patients. Anemia occurred in 10% of patients in both faldaprevir arms (12- and 24-week) and 5% of patients taking (PegIFN/RBV alone). Rash, photosensitivity, and jaundice occurred in </= 5% of faldaprevir patients (12- or 24-week arms). Further, AEs leading to the discontinuation of faldaprevir occurred in 7% (12-week) and 8% (24-week) of patients. In STARTVerso™4 to date, nausea has occurred in 28% and 44% of patients taking 120mg and 240mg faldaprevir regimens, respectively. Additionally, fatigue has occurred in 32% (120mg) and 35% (240mg) of patients, diarrhea has occurred in 25% (120mg) and 28% (240mg) of patients, headache has occurred in 24% (120mg) and 25% (240mg) of patients, asthenia has occurred in 26% (120mg) and 21% (240mg) of patients, and decreased appetite has occurred in 24% (120mg) and 20% (240mg) of patients. Thus far, discontinuation of faldaprevir due to AEs leading to the discontinuation of faldaprevir has occurred in 1% (120mg and 240mg) of patients. Serious AEs occurred in 14% (120mg) and 8% (240mg) of patients, resulting in one death from Stevens-Johnson syndrome (SJS) with onset 145 days after discontinuing treatment while on systemic antibiotics.

Additional Boehringer Ingelheim Data at the Meeting
Additional late breaking data from Boehringer Ingelheim's collaborative interferon-free trial with Presidio Pharmaceuticals will be presented on Monday, November 4. This ongoing Phase 2a study evaluates a 12-week, all-oral regimen of Boehringer Ingelheim's investigational compounds, faldaprevir and deleobuvir, in combination with Presidio's investigational pan-genotypic NS5
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... - On Aug. 20, at its annual meeting in ... (CMA) voted on and approved a delegate resolution opposing ... Bedrocan Cannabis Corp., a leading Canadian licensed producer of ... The CMA is quite right to point out ... plant material, including medicinal cannabis. While some patients, particularly ...
(Date:8/22/2014)... Research and Markets  has announced the addition of ... Technologies" report to their offering. ... you wish to expand your product line, you,ll know ... authors know you want to make effective product development ... improved revenues and take market share from your competition. ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... 2011 EMKinetics, Inc. announced today initiation of ... trial for patients suffering from urge incontinence and ... at 10-15 US centers.  Submission for CE mark ... the study.   EMKinetics, TranStim therapy builds on ...
... 2011 Masimo (NASDAQ: MASI ) announced ... period ended October 1, 2011, after the market closes on October ... at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted ... de Raad, Executive Vice President and Chief Financial Officer. ...
Cached Medicine Technology:EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 3
(Date:8/22/2014)... first time an oncogenic somatic mutation at amino acid ... been identified in small cell lung cancer (SCLC) tumors ... lines produced increased intracellular signaling and cell growth. , ... representing 15% of all lung cancers and is strongly ... cancer, has been extensively examined for genomic alterations and ...
(Date:8/22/2014)... Paying tuition and other related educational expenses ... for four nurse educators pursuing advanced degrees, thanks to ... Foundation for Nursing Education . This year’s recipients – ... than in 2013, thanks to these named NLN Foundation ... Marcil Endowment Funds, both donated by Kathy Mershon; the ...
(Date:8/22/2014)... New York, New York (PRWEB) August 22, 2014 ... ) continue to be filed in U.S. courts ... cardiovascular events due to their use of prescription ... to court documents, a new claim was filed ... California man who allegedly suffered life-threatening heart issues ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 CarePoint ... specialist in Internal Medicine, Geriatrics, Hospice and Palliative ... CarePoint Health Medical Group. Their system welcomes Dr. ... and experienced physicians comprise CarePoint Health Medical Group, ... in Hudson County, representing a wide range of ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Back-to-school time provides an opportunity ... into the family schedules, an expert suggests. "Forget ... year can also be the start of a new ... professor of kinesiology at the University of the Sciences ... With kids, extracurricular activities likely to build up, "it,s ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... Rheumatism (EULAR) welcomes the outcomes of yesterday,s Council of ... 7 December, ministers for health adopted Council Conclusions on ... States and the European Commission to adopt concrete, coordinated ... pleased to note that the Council Conclusions reflect many ...
... (HealthDay News) -- ,Women with localized breast cancer are less ... surgery, a new study finds. The researchers also found ... of the recurrence of localized cancer. The three-nation study ... common type of noninvasive breast cancer, who were followed for ...
... MDA recent study accepted for publication in The Endocrine ... (JCEM) has demonstrated a novel and accurate test for ... in 1,500 to 2,000 female live births and early ... and co-morbid conditions including cardiac and renal problems. ...
... CA (December 8, 2010) People who are neurotic often ... neurotic newlyweds have frequent sexual relations, their marital satisfaction ... counterparts, according to a study in the current ... Neuroticism is the tendency to experience negative ...
... HealthDay Reporter , TUESDAY, Dec. 7 (HealthDay News) -- Stool ... accurate for patients on a low-dose aspirin regimen, which is ... While therapeutic aspirin use was once feared to skew ... researchers found the test was significantly more sensitive for low-dose ...
... can be a life saver for patients needing immediate ... the process of activating them often delays treatment beyond ... print in Annals of Emergency Medicine, was ... multicenter, retrospective chart review, McMullan found that a majority ...
Cached Medicine News:Health News:EULAR welcomes Council action to tackle chronic diseases 2Health News:Radiation After Surgery Lowers Chances of Breast Cancer's Return 2Health News:Frequent sex protects marital happiness for neurotic newlyweds 2Health News:Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test 2Health News:Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test 3Health News:Even with helicopter EMS, hospital transfer can delay treatment for heart attacks 2Health News:Even with helicopter EMS, hospital transfer can delay treatment for heart attacks 3
Used to introduce large devices for vascular intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....
Medicine Products: